10/5/2026
AdvisorShares Trust holds 6.78% stake in Psyence Biomedical
The investment firm reports significant ownership in Psyence Biomedical as of September 2026.
Topic archive
u.s. securities and exchange commission
3 stories
9/28/2026
Psyence Biomedical secures $1.3M ibogaine licensing deal
Texas subsidiary gains exclusive U.S. rights to PsyLabs' ibogaine
9/2/2026
Psyence Biomedical files SEC document
The filing could signal strategic developments for the company.